Alto Neuroscience (NYSE:ANRO) Shares Down 7.2% – Here’s Why

Alto Neuroscience, Inc. (NYSE:ANRO) shares fell 7.2% during trading on Thursday . The company traded as low as $19.59 and last traded at $19.89. 36,007 shares traded hands during trading, a decline of 82% from the average session volume of 200,886 shares. The stock had previously closed at $21.43.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Jefferies Financial Group upped their target price on Alto Neuroscience from $15.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, November 12th. BTIG Research boosted their price objective on Alto Neuroscience from $27.00 to $28.00 and gave the company a “buy” rating in a research note on Tuesday, February 17th. Wall Street Zen raised Alto Neuroscience from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Robert W. Baird raised their target price on shares of Alto Neuroscience from $16.00 to $22.00 and gave the stock an “outperform” rating in a research report on Thursday, November 13th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Alto Neuroscience in a report on Monday, December 29th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $26.50.

Alto Neuroscience Trading Up 0.8%

The company has a market cap of $644.70 million, a price-to-earnings ratio of -9.06 and a beta of 2.52. The business has a fifty day simple moving average of $17.37 and a 200 day simple moving average of $12.31. The company has a quick ratio of 15.42, a current ratio of 15.42 and a debt-to-equity ratio of 0.20.

Institutional Trading of Alto Neuroscience

Several hedge funds and other institutional investors have recently made changes to their positions in ANRO. AlphaCore Capital LLC boosted its holdings in Alto Neuroscience by 100.0% during the second quarter. AlphaCore Capital LLC now owns 20,000 shares of the company’s stock worth $44,000 after buying an additional 10,000 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new position in Alto Neuroscience in the second quarter valued at about $85,000. Bank of Montreal Can acquired a new stake in shares of Alto Neuroscience during the 2nd quarter valued at approximately $25,000. Spruce Street Capital LP acquired a new stake in shares of Alto Neuroscience during the 4th quarter valued at approximately $3,967,000. Finally, Northwestern Mutual Wealth Management Co. boosted its stake in shares of Alto Neuroscience by 14,567.0% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 212,672 shares of the company’s stock worth $3,786,000 after acquiring an additional 211,222 shares in the last quarter.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.